Emerging roles of the acid sphingomyelinase/ceramide pathway in metabolic and cardiovascular diseases:Mechanistic insights and therapeutic implications  

作　　者：Hong-Ni Wang Ye Wang Si-Yao Zhang Lan Bai 

机构地区：[1]State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases,Gannan Innovation and Translational Medicine Research Institute,Gannan Medical University,Ganzhou 341000,Jiangxi Province,China

出　　处：《World Journal of Cardiology》2025年第2期9-21,共13页世界心脏病学杂志(英文)

基　　金：Supported by Ganzhou City’s“Light of the Soviet Area”Talent Project,No.GZSQZG202301009。

摘　　要：Metabolic diseases have emerged as a leading cause of mortality from non-communicable diseases,posing a significant global public health challenge.Al-though the association between ceramides(Cers)and metabolic diseases is well-established,the role of the acid sphingomyelinase(ASMase)/Cer pathway in these diseases remains underexplored.This review synthesizes recent research on the biological functions,regulatory mechanisms,and targeted therapies related to the ASMase/Cer pathway in metabolic conditions,including obesity,diabetes,non-alcoholic fatty liver disease,and cardiovascular disease.The effects of the ASMase/Cer pathway on metabolic disease-related indicators,such as glycolipid metabolism,insulin resistance,inflammation,and mitochondrial homeostasis are elucidated.Moreover,this article discusses the therapeutic strategies using ASMase/Cer inhibitors for inverse prevention and treatment of these metabolic diseases in light of the possible efficacy of blockade of the ASMase/Cer pathway in arresting the progression of metabolic diseases.These insights offered herein should provide insight into the contribution of the ASMase/Cer pathway to metabolic diseases and offer tools to develop therapeutic interventions for such pathologies and their severe complications.

关 键 词：Acid sphingomyelinase CERAMIDE Metabolic and cardiovascular diseases Glycolipid metabolism Inflammation Mitochondrial homeostasis 

分 类 号：R57[医药卫生—消化系统]